One analyst who wrote on the Nerualstem press release, compared the reported ALSFRS-R changes in the Phase 2 clinical trial to a historical dataset, PRO-ACT. According to that person's analysis, when the data from all participants are analyzed together against the historical control group, it indicates the treatment may have had an overall adverse effect on disease progression.

The International Symposia of ALS/MND Research is the preeminent meeting of the global ALS/MND community. It brings together hundreds of neuroscientists, neurologists, and associated health professionals for three days in a different country each year.